ALG-055009
ALG-055009-303
Phase 2 small_molecule completed
Quick answer
ALG-055009 for NASH is a Phase 2 program (small_molecule) at Aligos Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aligos Therapeutics
- Indication
- NASH
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed